本报北京电（张子震、刘胜德）第15届北京大学消化肿瘤论坛暨中国胃肠肿瘤临床研究协作组 （CGOG）年会日前在北京举行。本次会议以"创新、精准、聚力"为主题，立足消化系统肿瘤的精准诊 疗与转化研究，聚焦最新研究进展和方向，积极推进创新诊疗模式和新药研发。 会上，国家蛋白质科学中心理事长贺福初院士介绍了人体蛋白质组导航计划（π-HuB计划），旨在通过 蛋白质组的复杂性与动态性，揭示生命系统的结构与功能基础。计划的首要任务是挖掘人体蛋白质中与 生命相关的信息，设定了四大目标：一是绘制人体蛋白质组的层次结构图谱；二是构建蛋白质组状态空 间图谱，追踪蛋白质谱系；三是建立元人体数字模型，进行数字化人体结构表征；四是在蛋白质组状态 空间中进行导航，预测疾病状态、预判疾病风险，并预警亚健康和重大疾病的发生。蛋白质组学驱动的 肿瘤精准医学时代的到来，为消化道肿瘤等疾病的诊断与治疗带来了显著的突破与益处。 针对上消化道肿瘤危害国人健康且治疗手段匮乏，北京大学肿瘤医院沈琳教授提出"B to B"双向转化研 究模式，针对HER2、EGFR和CLDN18.2等靶点探索新的治疗方案。据其介绍，细胞治疗已经在实体瘤 领域大显身手，免疫治疗 ...

Core Insights - Illumina announced the acquisition of SomaLogic for $350 million in cash, aimed at enhancing its position in the growing proteomics market and accelerating its multi-omics strategy for 2024 [1][3] - The acquisition is based on a prior collaboration established in December 2021, focusing on integrating SomaLogic's protein detection technology into Illumina's NGS platform [3][4] - The global proteomics market is projected to grow from $33.6 billion in 2024 to $60.5 billion by 2029, with a compound annual growth rate (CAGR) of 12.4% [9] Company Strategy - Illumina's CEO stated that the acquisition will enhance the value of the NovaSeq X product and unlock greater potential for future advancements [3] - The integration of SomaLogic's technology with Illumina's scalable NGS platform and analysis software is expected to accelerate technological development in proteomics and reduce research time and costs [3] - The company aims to complete the acquisition by mid-2026, pending regulatory approvals, while both companies will continue to operate independently until then [4] Market Context - Illumina holds over 80% of the global gene sequencing market but has faced revenue declines and significant losses, particularly a projected loss of $1.223 billion in 2024 [6] - The company has been impacted by being placed on the "unreliable entity list" in China, affecting its business in the Greater China region [6] - The competitive landscape is intensifying, with rivals like Roche Diagnostics and BGI encroaching on Illumina's market share [6] Industry Trends - The proteomics field is seen as a critical area for future diagnostics and drug development, with the potential to discover new biomarkers and therapeutic targets [7] - Recent acquisitions in the proteomics space, such as Thermo Fisher's $3.1 billion purchase of Olink Holding AB, indicate a growing interest and investment in this sector [10] - Illumina's acquisition of SomaLogic is expected to strengthen its capabilities in the high-growth proteomics market, with profitability anticipated by 2027 [10]

近日，华熙生物公众号发布《关于透明质酸和重组胶原蛋白的传言与真相》。当中谈到，资本市场概念 切换带来的关于透明质酸和重组胶原蛋白的误导性认知，已经远远偏离了科学和产业发展的基本面。如 果不加以纠正，不但会影响到华熙生物等一大批企业的经营环境，也会给以重组胶原蛋白为经营概念的 企业带来资源错配和风险，因为任何从业者都不可能绕开生物学的基本规律和产业的基本规律走得太 远。 近几年基于基因工程表达的重组胶原蛋白获得了快速发展，华熙生物也在从事相关的研究和产业转化， 华熙生物的重组胶原蛋白原料已初步经过市场验证，正持续供应给其他行业企业。但有几个基本的事实 一直在提醒我们把握好"先行先试"和"全球领先"之间的表述差异：首先，"重组的"胶原蛋白只是胶原蛋 白研究和产业转化当中很小的一个分支，整个蛋白质组学研究，包括胶原蛋白研究和转化的制高点依然 掌握在生命科学研究机构和医药企业手中，并不掌握在医美或化妆品公司，资本市场不能不顾这些基本 事实去引导对"全球领先"的错误预期。 其次，以基于重组胶原蛋白的医美三类械证书为例，国际上还没有相关的准入批复，这当然说明我们在 先行探索，另一方面也说明我们需要更长的实践观察周期。 而 ...

Summary of Bruker (BRKR) 2025 Conference Call Company Overview - **Company**: Bruker Corporation (BRKR) - **Event**: 2025 Conference Call held on June 04, 2025 Key Industry Insights - **Industry**: Mass Spectrometry and Proteomics - **Market Trends**: The mass spectrometry market is experiencing significant innovation, particularly in proteomics and metabolomics, with a focus on high sensitivity and throughput solutions [3][10][12] Core Product Innovations 1. **TIMS Ultra and AIP**: - New product launched to enhance MSMS sensitivity and bandwidth, allowing for more peptides and proteins to be analyzed [5][7] - Significant advancements in single-cell proteomics, enabling analysis of smaller cells than previously possible [8] 2. **TIMS Metabo Instrument**: - Aimed at the high-resolution accurate mass market for small molecules, targeting applications in PFAS research, toxicology, and metabolomics [11][12] - Expected to double the market opportunity for Bruker, potentially reaching a $200 million market share [15] 3. **TIMS Omni**: - A revolutionary mass spectrometer combining TIMS technology with Omni Trap, enabling top-down proteomics and functional proteomics [17][18] - Positioned to create a new category in mass spectrometry with no direct competition [19] Financial Outlook - **Revenue Guidance**: Anticipated moderate growth in 2026, with expectations of organic growth between 6% to 8% [32] - **Cost Management**: Bruker is implementing cost-cutting measures, including reducing operational costs in European sites and optimizing R&D spending [33][35] Market Dynamics - **Academic Market**: Anticipated decline in academic spending by 20-25% due to budget constraints, impacting overall revenue [22][30] - **Defense and Homeland Security**: Notable growth in the detection business for radiological and chemical threats, with potential revenue increases of $20 million next year [38][39] Emerging Markets and Opportunities - **Semiconductor and AI**: Strong demand in metrology for high-performance computing and AI applications, expected to grow from 8% to potentially 12% of total revenue [45][46] - **China Market**: Potential for stimulus-driven growth in high-end research tools, although timing remains uncertain [51][52] Strategic Developments - **Cell Analysis and Diagnostics**: Launch of a new benchtop product aimed at broadening market access for antibody discovery and cell line selection [54][55] - **Spatial Biology**: Continued investment in spatial biology technologies, enhancing capabilities in multi-omics and improving throughput and detection efficiency [61][62] Conclusion - Bruker is positioned for growth through innovative product offerings in mass spectrometry and proteomics, despite facing challenges in academic funding and market uncertainties. The company is strategically focusing on high-growth areas such as biopharma, diagnostics, and advanced manufacturing technologies.

撰文丨王聪 编辑丨王多鱼 排版丨水成文 癌症 是一组异质性疾病，其特征是恶性细胞不受控制地生长和扩散，逃脱了正常的检查和平衡机制。肿瘤的分子特征可用于临床干预，以实现个性化治疗。 癌症基因组图谱 （TCGA） 和国际癌症基因组联盟 （ICGC） 的大规模基因组学研究旨在编录主要的致癌基因组改变，并提供一份全面的癌症基因组特征"图 谱"。对 30 多种人类癌症的大规模队列进行广泛的基因组测序，并结合对单个癌症类型的综合分析以及全面的泛癌分析，揭示了细胞异常的非常复杂的图景，拓 展了当前对肿瘤发生机制的认识，并创新了分子诊断方法。尽管取得了这些进展，但要预测肿瘤中的基因组/表观基因组和转录组改变如何影响下游蛋白质的表达 和活性，仍颇具挑战性。 蛋白质 是细胞中的功能单位，也是大多数疗法的作用靶点。因此，仅依据基因组/表观基因组和转录组特征来选择靶向治疗，仍有改进空间。蛋白质组不仅能够拓 展我们对细胞动态分子行为的理解，帮助揭示癌症表型的形成机制，还可能改善诊断和治疗选择。然而，迄今为止，大多数癌症蛋白质组学研究都集中在单一癌 症类型上。 2025 年 5 月 29 日，阿姆斯特丹自由大学 Connie Jimen ...

Quantum-Si (QSI) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 Day, and thank you for standing by. Welcome to the Quantum SI First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To answer your question, please press 11 ag ...

Seer (SEER) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the SEER First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please pr ...